Laura Tuzza

Dr. Laura Tuzza


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2023 in Cancers
Verified
Journal Article
Open access
PDF file
MMMatia Martucci
Matia Martucci
RRRosellina Russo
Rosellina Russo
CGCarolina Giordano
Carolina Giordano
CSChiara Schiarelli
Chiara Schiarelli
GDGabriella D’apolito
Gabriella D’apolito
SGSimona Gaudino
Simona Gaudino
MRI plays a key role in the evaluation of post-treatment changes, both in the immediate post-operative period and during follow-up. There are many different treatment’s lines and many different neuroradiological findings according to the treatment chosen and the clinical timepoint at which MRI is performed. Structural MRI is often insufficient to correctly interpret and define treatment-related changes. For that, advanced MRI modalities, including perfusion and permeability imaging, diffusion tensor imaging, and magnetic resonance spectroscopy, are increasingly utilized in clinical practice to characterize treatment effects more comprehensively. This article aims to provide an overview of the role of advanced MRI modalities in the evaluation of treated glioblastomas. For a didactic purpose, we choose to divide the treatment history in three main timepoints: post-surgery, during Stupp (first-line treatment) and at recurrence (second-line treatment). For each, a brief introduction, a temporal subdivision (when useful) or a specific drug-related paragraph were provided. Finally, the current trends and application of radiomics and artificial intelligence (AI) in the evaluation of treated GB have been outlined.

13 June 2025 in Clinical Radiology
Verified
Journal Article
Open access
RCR. Calandrelli
R. Calandrelli
FPfabio pilato
fabio pilato
LTLaura Tuzza
Laura Tuzza
CAC. Arpaia
C. Arpaia
AGA. De Gioia
A. De Gioia
DRD.M. Romeo
D.M. Romeo
Develop a combined magnetic resonance imaging (MRI) scoring system to categorise brain abnormalities in symptomatic newborns with congenital cytomegalovirus (cCMV) infection and evaluate its usefulness in predicting long-term neurological outcomes. cCMV infection onset during pregnancy and clinical severity at birth were assessed; the overall 3-year clinical outcome for language, motor, and cognitive impairments was determined based on domain scores. We developed an MRI score combining visual-semiquantitative findings with volumetric data from brain regions to assess overall brain damage, including cortex abnormalities, white matter changes, calcifications, hippocampal dysplasia, brain volume reductions, and increased ventricular volume. The final cumulative score was the sum of all regional subscores, with higher scores indicating more severe damage. Twenty-eight symptomatic cCMV newborns from cytomegalovirus (CMV)-infected pregnant women were studied, with 21 infected in the first two trimesters (early infection) and 7 in the third trimester (late infection). At diagnosis, 21.4% had mild, 7.1% had moderate, and 71.4% had severe symptoms. Long-term neurological outcomes were observed in 82.1% of the children. An association between clinical severity of cCMV and infection timing (early/late) was found (P<0.001). The MRI score correlated with clinical outcomes (P=0.047; r=0.378) and identified infants at a high risk for severe impairment (P=0.033, odds ratio: 1.488) with a cut-off score of 4 distinguishing between higher and lower impairment levels (Area Under the Curve (AUC): 0.753, P=0.006). The combined MRI score provides a reproducible tool to predict early neurodevelopmental impairments in cCMV patients, aiding clinicians in management and counselling.